Patient Questions and Expert Answers in Psoriasis: Clinical Pearls

Please join Mark G. Lebwohl, MD, Joel M. Gelfand, MD, MSCE, and Jeffrey M. Weinberg, MD, for a panel discussion of complex cases in psoriatic disease.

This activity is a collaboration between the National Psoriasis Foundation and Medscape, LLC. To view the activity, please click on the link below. You will be prompted to login to Medscape prior to viewing the activity. 

https://www.medscape.org/viewarticle/884822

This activity is supported by educational grants from Abbvie, Inc., and Lilly.

Accreditation Statement

The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit

The National Psoriasis Foundation designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Target Audience

Dermatologists, Rheumatologists, Allied Health, Primary Care

Learning Objectives

Upon completion of this activity, participants will:

  • Demonstrate greater confidence in the ability to identify and consider key factors in creating comprehensive management plans for patients with psoriasis
  • Have greater competence related to treating patients with moderate-to-severe psoriasis based on severity and patient characteristics
  • Have increased knowledge regarding the appropriate strategies for counseling patients with psoriasis and comorbid conditions such as psoriatic arthritis
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    Accreditation

    This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint providership of Oregon Health & Science University (OHSU) and the National Psoriasis Foundation. OHSU is accredited by the ACCME to provide CME for physicians.

    Credit

    OHSU School of Medicine, Division of CME, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 CE
Course opens: 
01/29/2018
Course expires: 
01/29/2019
Event starts: 
02/28/2018 - 3:00pm
Event ends: 
02/28/2018 - 4:00pm
Cost:
$0.00
Rating: 
0
Mark Lebwohl, MD 
Chair, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
 
Dr. Lebwohl has disclosed the following relevant financial relationships: 
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Janssen Research & Development, LLC; Kadmon Corporation, LLC; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; Vidac
 
Joel Gelfand, MD 
Professor and Vice-Chair, Dermatology and Epidemiology; Vice-Chair of Clinical Research; Director of Psoriasis and Phototherapy Treatment Center, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
 
Dr. Gelfand has disclosed the following relevant financial relationships: 
Served as an advisor or consultant for: Coherus Biosciences; Dermira Inc.; Dr. Reddy's Laboratories Ltd.; Janssen Pharmaceuticals, Inc.; Menlo Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Lilly
Received grants for clinical research from: AbbVie Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi 
Other: Co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma
 
Jeffrey Weinberg, MD
Associate Clinical Professor, Dermatology at Mount Sinai St. Luke's, West, and Beth Israel Medical Center, New York, New York

Dr. Weinberg has disclosed the following relevant financial relationships: 
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Celgene Corporation; LEO Pharma Inc.; Lilly; Valeant Pharmaceuticals International 
Received grants for clinical research from: AbbVie Inc.; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation

Accreditation Period

Course opens: 
01/29/2018
Course expires: 
01/29/2019

Price

Cost:
$0.00
Please login to take this course.